Compression Spinal Cord Injury Model Development Service
Are you currently facing long drug development cycles, challenges in validating therapeutic interventions, or difficulty in accurately replicating human spinal cord injury (SCI)? Our Advanced Preclinical SCI Modeling Services help you accelerate drug discovery, validate therapeutic interventions, and accurately replicate human SCI through state-of-the-art compression devices, comprehensive outcome analysis, and expert scientific guidance.
Animal SCI models are indispensable for understanding traumatic SCI mechanisms and evaluating experimental therapeutic interventions. Over the past 25 years, significant advancements have been made in developing consistent, reproducible, and reliable animal SCI models. These models are categorized by injury mechanism, including contusion, compression, distraction, dislocation, transection, or chemical. Creative Biolabs leverages these advancements to provide robust preclinical platforms.
How Our Compression Spinal Cord Injury Models Can Assist Your Project
At CBL, we provide tailored study designs, precise injury induction, comprehensive data analysis, and expert interpretation to accelerate your research timelines. Our solutions are designed to generate robust, translational data that directly informs your critical go/no-go decisions in therapeutic development. We ensure that your project benefits from our two decades of experience in navigating the complexities of SCI research, delivering actionable insights and reliable results.
Discover How We Can Help - Request a Consultation
Workflow: From Concept to Breakthrough
Our methodical workflow ensures a seamless and efficient research process, designed for clarity and precision, and suitable for visualization as a flowchart.
- Required Starting Materials:
To initiate your project, we typically require:
- Target Compound/Therapeutic Agent: Detailed information on the therapeutic candidate, including its mechanism of action, stability, and any preliminary efficacy data.
- Specific Research Questions/Hypotheses: Clear articulation of your study objectives, desired outcomes, and the specific SCI mechanisms you aim to investigate.
- Desired Injury Severity/Model Type: Your preferred compression SCI model (e.g., contusion, clip, balloon) and the level of injury severity required for your research.
- Final Deliverables:
Upon project completion, you will receive:
- Comprehensive Study Report: A detailed document summarizing the entire study, including methodology, results, statistical analysis, and expert interpretation.
- Raw Data Files: All raw data from behavioral assessments, histological analyses, and molecular assays, provided in accessible formats for your internal review.
- High-Resolution Histological Images/Analysis: Annotated images and quantitative data from tissue sections, illustrating cellular and structural changes.
- Estimated Timeframe:
The typical timeframe for a compression SCI study ranges from 8 to 16 weeks, depending on the complexity of the model, the duration of therapeutic intervention, and the scope of outcome measures required for your specific project.
Why Choose Us?
Choosing CBL means partnering with a leader in preclinical SCI research. Our 20 years of experience, coupled with state-of-the-art facilities and a team of dedicated neuroscientists, ensures unparalleled precision and reliability in every study. We are committed to providing customizable models that accurately mimic human SCI, minimizing surgical artifacts, and considering diverse patient demographics to maximize translational impact. Our rigorous quality control and comprehensive analytical capabilities provide robust data, accelerating your path to breakthrough therapies.
Experience the Advantage - Get a Quote Today
Customer Reviews
"Enhanced Data Reliability Using CBL's compression SCI models in our research has significantly improved the reliability and consistency of our preclinical data, allowing us to confidently move forward with our lead compounds. The detailed histological analysis provided invaluable insights into tissue sparing and axonal regeneration, far surpassing our previous internal efforts." 2024, Dr. A***n Smith.
"Streamlined Development CBL's expertise in tailoring their compression SCI models to our specific therapeutic mechanism greatly facilitated our antibody development project. Their team's understanding of acute vs. sustained compression effects helped us refine our dosing strategy, leading to a significant reduction in animal usage and overall project costs compared to alternative approaches." 2023, Dr. L***a Chen.
"Unmatched Translational Insights The comprehensive behavioral and electrophysiological assessments performed by CBL using their compression SCI models provided us with a truly translational understanding of our gene therapy's efficacy. Their ability to minimize surgical artifacts meant the observed functional improvements were directly attributable to our intervention, giving us confidence for future clinical trials." 2025, Prof. M***k Jones.
Compression Spinal Cord Injury Models
Compression is a predominant mechanism of human SCI, often resulting from vertebral fractures, disc herniations, or tumors. Preclinical models that accurately replicate this injury type are invaluable for translational research. At CBL, we employ a range of sophisticated compression SCI models, each offering unique advantages for specific research questions.
-
Clip Compression Models
- Mechanism: A standardized vascular clip (e.g., aneurysm clip) is applied to the spinal cord for a defined duration (e.g., 30 seconds to 1 minute), causing sustained compression. This method can also induce ischemia/reperfusion type SCI.
- Advantages: Controlled and measurable force for graded injury severity. Introduces sustained compression relevant to prolonged entrapment scenarios. Simple, inexpensive, and adaptable for use in all regions of the spine and various species (murine, rats, pigs).
- Applications: Useful for investigating the effects of sustained compression, ischemia-reperfusion injury, and interventions targeting chronic SCI pathology.
-
Calibrated Forceps Compression
- Mechanism: A pair of calibrated forceps is compressed around the spinal cord to a specific width, using a spacer, for a select duration.
- Advantages: Simple, inexpensive, and requires limited resources. Capable of producing graded SCI by varying compression widths.
- Applications: Useful for studies where a sustained, controlled compression without a significant acute impact is desired, particularly for investigating chronic effects.
Essential Outcome Measures: Quantifying Therapeutic Efficacy
Robust preclinical research demands rigorous and objective outcome measures. At CBL, our comprehensive analytical capabilities ensure that every study yields reliable and interpretable data. Key outcome measures we employ include:
Outcome Measures | Description |
Behavioral Assessments |
|
Histopathological Analysis |
|
Molecular and Biochemical Analysis |
|
What We Can Offer
At CBL, our offerings extend beyond just models. We provide a holistic partnership designed to support your entire preclinical research journey in spinal cord injury. Our comprehensive suite of services ensures that you have access to the most advanced tools and expert guidance for your specific project needs. We are committed to delivering high-quality, translational data that directly informs your therapeutic development.
Related Services
To further support your drug discovery and development journey in neurological disorders, CBL offers a suite of complementary services and model variations:
- Other SCI Model Types
- Neuroinflammation Assays
- Neurodegenerative Disease Models
- Biomarker Discovery & Validation
- Histology & Pathology Services
Ready to advance your spinal cord injury research? Our team of experts is eager to discuss your specific project requirements and demonstrate how our tailored solutions can accelerate your path to breakthrough therapies.
Contact Our Team for More Information and to Discuss Your Project.
- iNeuMab™ Anti-FGFR1 Antibody (NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-GD2 Antibody (NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody (NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- iNeuMab™ Anti-Alpha Synuclein Antibody (NRP-0422-P614) (Cat#: NRP-0422-P614)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- iNeu™ Human Neural Stem Cell Line (Cat#: NCL200552ZP)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Rat Muller Cell (Cat#: NCL2110P040)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)